Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective
REVIEW

Life expectancy of HIV-positive adults: a review

Margaret T. May A B and Suzanne M. Ingle A
+ Author Affiliations
- Author Affiliations

A School of Social and Community Medicine, University of Bristol, Bristol BS8 2PS, UK.

B Corresponding author. Email: m.t.may@bristol.ac.uk

Sexual Health 8(4) 526-533 https://doi.org/10.1071/SH11046
Submitted: 11 March 2011  Accepted: 9 June 2011   Published: 30 September 2011

Abstract

We review studies estimating life expectancy (LE), the average number of additional years a person can expect to live, for HIV-positive adults and show variation by sociodemographic factors and level of immunosuppression. The LE of patients starting antiretroviral therapy early in the course of HIV infection and attaining restoration of a normal CD4 count may approach that of the general population. Improvements in treatment and the associated increase in LE imply that increasing numbers of HIV-positive patients will live to older age. Late diagnosis and presentation to care and treatment not concordant with guidelines contribute to reducing LE.

Additional keywords: aging, antiretroviral therapy, CD4, immunosuppression, prognosis, sociodemographics.


References

[1]  World Health Organization (WHO). Global health indicators: Part 2. Geneva: WHO; 2008. Available online at: http://www.who.int/whosis/whostat/EN_WHS08_Table4_HSR.pdf [verified February 2011].

[2]  Zwahlen M, Harris RJ, Hogg R, Costagliola D, May M, de Wolf F, et al Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in eight industrialized countries. Int J Epidemiol 2009; 38 1624–33.

[3]  Cooper DA. Life and death in the cART era. Lancet 2008; 372 266–7.
Life and death in the cART era.CrossRef |

[4]  Lohse N, Hansen AB, Gerstoft J, Obel N. Improved survival in HIV-infected persons: consequences and perspectives. J Antimicrob Chemother 2007; 60 461–3.
Improved survival in HIV-infected persons: consequences and perspectives.CrossRef |

[5]  Santrock J. A topical approach to life-span development. New York: McGraw-Hill; 2007.

[6]  Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367 817–24.
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries.CrossRef |

[7]  United Nations (UN). World population prospects, the 2010 Revision. New York: UN; 2008. Available online at: http://esa.un.org/unpd/wpp/Excel-Data/mortality.htm [verified February 2011].

[8]  Chigwedere P, Seage GR, Gruskin S, Lee TH. Estimating the lost benefits of antiretroviral drug use in South Africa. J Acquir Immune Defic Syndr 2008; 49 410–5.
Estimating the lost benefits of antiretroviral drug use in South Africa.CrossRef |

[9]  Mahy M, Stover J, Stanecki K, Stoneburner R, Tassie JM. Estimating the impact of antiretroviral therapy: regional and global estimates of life-years gained among adults. Sex Transm Infect 2010; 86 ii67–71.
Estimating the impact of antiretroviral therapy: regional and global estimates of life-years gained among adults.CrossRef |

[10]  ART-CC Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372 293–9.
Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies.CrossRef |

[11]  Gardner JW, Sanborn JS. Years of potential life lost (YPLL) – what does it measure? Epidemiology 1990; 1 322–9.
Years of potential life lost (YPLL) – what does it measure?CrossRef |

[12]  Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, et al The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194 11–9.
The survival benefits of AIDS treatment in the United States.CrossRef |

[13]  UNAIDS. reference group on estimates map. Improved methods and assumptions for estimation of the HIV/AIDS epidemic and its impact: recommendations of the UNAIDS reference group on estimates, modelling and projections. AIDS 2002; 16 W1–14.

[14]  Bulatao R. Population and mortality after AIDS. In: Jamison D, Feachem R, Makgoba M, editors. Disease and mortality in sub-Saharan Africa, 2nd edn. Washington, DC: World Bank; 2006. Available online at: http://www.ncbi.nlm.nih.gov/books/NBK2299/ [verified July 2011].

[15]  Koblin BA, Hessol NA, Zauber AG, Taylor PE, Buchbinder SP, Katz MH, et al Increased incidence of cancer among homosexual men, New York City and San Francisco, 1978–1990. Am J Epidemiol 1996; 144 916–23.

[16]  Babiker A, Darby S, De Angelis D, Kwart D, Porter K, Beral V, et al Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Lancet 2000; 355 1131–7.
Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis.CrossRef |

[17]  Sterne JA, Hernan MA, Ledergerber B, Tilling K, Weber R, Sendi P, et al Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005; 366 378–84.
Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study.CrossRef |

[18]  Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352 1725–30.
Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.CrossRef |

[19]  Hogg RS, Heath KV, Yip B, Craib KJ, O’Shaughnessy MV, Schechter MT, et al Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998; 279 450–4.
Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.CrossRef |

[20]  Blower SM, Gershengorn HB, Grant RM. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 2000; 287 650–4.
A tale of two futures: HIV and antiretroviral therapy in San Francisco.CrossRef |

[21]  Wood E, Low-Beer S, Bartholomew K, Landolt M, Oram D, O’Shaughnessy MV, et al Modern antiretroviral therapy improves life expectancy of gay and bisexual males in Vancouver’s West End. Can J Public Health 2000; 91 125–8.

[22]  Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, et al Survival of persons with and without HIV infection in Denmark, 1995–2005. Ann Intern Med 2007; 146 87–95.

[23]  van Sighem AI, Gras LA, Reiss P, Brinkman K, de Wolf F. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS 2010; 24 1527–35.
Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals.CrossRef |

[24]  Losina E, Schackman BR, Sadownik SN, Gebo KA, Walensky RP, Chiosi JJ, et al Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis 2009; 49 1570–8.
Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy.CrossRef |

[25]  Harrison KM, Song R, Zhang X. Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. J Acquir Immune Defic Syndr 2010; 53 124–30.
Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States.CrossRef |

[26]  May M, Gompels M, Sabin C. Impact on life expectancy of late diagnosis and treatment of HIV-1 infected individuals: UK CHIC. Tenth International Congress on Drug Therapy in HIV Infection; 2010; Nov 7–11; Glasgow, UK.

[27]  Laing SP, Swerdlow AJ, Slater SD, Botha JL, Burden AC, Waugh NR, et al The British Diabetic Association cohort study I: all-cause mortality in patients with insulin-treated diabetes mellitus. Diabet Med 1999; 16 459–65.
The British Diabetic Association cohort study I: all-cause mortality in patients with insulin-treated diabetes mellitus.CrossRef |

[28]  Bansi L, Sabin C, Delpech V, Hill T, Fisher M, Walsh J, et al Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations. HIV Med 2010; 11 432–8.

[29]  Lampe FC, Smith CJ, Madge S, Kinloch-de LS, Tyrer M, Sabin CA, et al Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004. Arch Intern Med 2007; 167 692–700.
Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004.CrossRef |

[30]  Bansi LK, Benzie AA, Phillips AN, Portsmouth S, Hill T, Leen C, et al Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression? AIDS 2008; 22 349–56.
Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?CrossRef |

[31]  El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ, Darbyshire J, et al Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med 2008; 149 289–99.

[32]  Lodwick RK, Smith CJ, Youle M, Lampe FC, Tyrer M, Bhagani S, et al Stability of antiretroviral regimens in patients with viral suppression. AIDS 2008; 22 1039–46.
Stability of antiretroviral regimens in patients with viral suppression.CrossRef |

[33]  UK Collaborative Group on HIV Drug Resistance, UK Collaborative HIV Cohort Study, UK Register of HIV Seroconverters. Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. AIDS 2007; 21 1035–9.
Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom.CrossRef |

[34]  Willig JH, Abroms S, Westfall AO, Routman J, Adusumilli S, Varshney M, et al Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS 2008; 22 1951–60.
Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy.CrossRef |

[35]  Kitahata MM, Van Rompaey SE, Dillingham PW, Koepsell TD, Deyo RA, Dodge W, et al Primary care delivery is associated with greater physician experience and improved survival among persons with AIDS. J Gen Intern Med 2003; 18 95–103.
Primary care delivery is associated with greater physician experience and improved survival among persons with AIDS.CrossRef |

[36]  Chadborn TR, Delpech VC, Sabin CA, Sinka K, Evans BG. The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000–2004). AIDS 2006; 20 2371–9.
The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000–2004).CrossRef |

[37]  Easterbrook PJ, Phillips AN, Hill T, Matthias R, Fisher M, Gazzard B, et al Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK. HIV Med 2008; 9 47–56.
Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK.CrossRef |

[38]  Scherrer A, Ledergerber B, von Wyl V, Boni J, Burgisser P, Yerly S, et al. Effect of HIV-1 subtype on virologic outcomes in Caucasian patients receiving cART in Switzerland. 18th Conference on Retroviruses and Opportunistic Infections; 2011 Feb 27; Boston, USA.

[39]  Braitstein P, Boulle A, Nash D, Brinkhof MW, Dabis F, Laurent C, et al Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. J Womens Health (Larchmt) 2008; 17 47–55.
Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration.CrossRef |

[40]  Gazzard BG, Anderson J, Babiker A, Boffito M, Brook G, Brough G, et al British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9 563–608.
British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008.CrossRef |

[41]  Pozniak A, Gazzard B, Anderson J, Babiker A, Churchill D, Collins S, et al British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2003; 4 1–41.
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy.CrossRef |

[42]  Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med 2002; 137 381–433.

[43]  Panel on Antiretroviral Guidelines for Adults and Adolescents (PAGAA). Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services USA; January 10, 2011; 1–166. Available online at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf [verified May 2011].

[44]  Granich R, Crowley S, Vitoria M, Smyth C, Kahn JG, Bennett R, et al Highly active antiretroviral treatment as prevention of HIV transmission: review of scientific evidence and update. Curr Opin HIV AIDS 2010; 5 298–304.

[45]  World Health Organization (WHO). Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach. Geneva: WHO; 2004. Available online at: http://www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf [verified May 2011].

[46]  World Health Organization (WHO). Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Geneva: WHO; 2010. Available online at: http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf [verified May 2011].

[47]  Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360 119–29.
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.CrossRef |

[48]  May M, Sterne JA, Sabin C, Costagliola D, Justice AC, Thiebaut R, et al Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007; 21 1185–97.
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies.CrossRef |

[49]  Lanoy E, May M, Mocroft A, Phillip A, Justice A, Chene G, et al Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. AIDS 2009; 23 2199–208.
Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements.CrossRef |

[50]  Lewden C, The Mortality Working Group of COHERE. Time with CD4 cell count above 500 cells/mm3 allows HIV-infected men, but not women, to reach similar mortality rates to those of the general population: a 7-year analysis. 17th Conference on Retroviruses and Infections; 2010 Feb 16–19; San Francisco, USA.

[51]  ART-CC Causes of death in HIV-1 infected patients treated with antiretroviral therapy 1996–2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50 1387–96.
Causes of death in HIV-1 infected patients treated with antiretroviral therapy 1996–2006: collaborative analysis of 13 HIV cohort studies.CrossRef |

[52]  Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, Lambert PC, et al Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008; 300 51–9.
Changes in the risk of death after HIV seroconversion compared with mortality in the general population.CrossRef |

[53]  Powderley W. Growing old with HIV – dealing with co-morbidities. 10th International Congress on Drug Therapy in HIV Infection; 2010 Nov 7; Glasgow, UK.

[54]  Back D. HIV therapy in an ageing population – the challenge of polypharmacy. 10th International Congress on Drug Therapy in HIV Infection; 2010 Nov 7; Glasgow, UK.

[55]  Marzolini C, Elzi L, Gibbons S, Weber R, Fux C, Furrer H, et al Prevalence of comedications and effect of potential drug–drug interactions in the Swiss HIV Cohort Study. Antivir Ther 2010; 15 413–23.
Prevalence of comedications and effect of potential drug–drug interactions in the Swiss HIV Cohort Study.CrossRef |

[56]  Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, et al Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society – USA panel. JAMA 2010; 304 321–33.
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society – USA panel.CrossRef |



Rent Article (via Deepdyve) Export Citation Cited By (39)

View Altmetrics